story of the week
Efficacy and Safety of an Ocrelizumab Biosimilar vs the Originator Product in Patients With Relapsing MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Scientific Reports
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial
Sci Rep 2024 Oct 22;14(1)24921, MA Sahraian, R Abolfazli, V Shaygannejad, F Ashtari, N Majdinasab, S Navardi, SM Baghbanian, B Sedighi, A Naser Moghadasi, MA Nahayati, H Ghalyanchi Langroodi, SE Mohammadianinejad, N Beladi Moghadam, H Ayromlou, A Nikseresht, M Ghiasian, N Razazian, E Asadollahzadeh, A Sabzvari, H Kafi, S AlbooyehFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.